International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting (original) (raw)
Related papers
The Journal of rheumatology, 2014
In the United States, access to care is the number one issue facing our patients with dermatological conditions. In part, this is because we do not have outcome measures that are useful in clinical practice and available in databases where payers and governmental agencies can compare the performance of physicians and treatments. There is a growing recognition that insufficient attention has been paid to the outcomes measured in clinical trials and subsequently in clinical practice. The International Dermatology Outcome Measures group includes all willing stakeholders: patients, physicians, payers, and pharmaceutical scientists. As reported herein, the group's goal is to develop outcome measures in dermatology that address the needs of all involved.
Journal of the European Academy of Dermatology and Venereology, 2020
is involved in performing clinical trials with many pharmaceutical industries including Novartis, Abbvie, Lilly, Regeneron, Sanofi, Boehringer, Leopharma, UCB, Pfizer, Amgen, Celgene that manufacture drugs used for the treatment of Accepted Article This article is protected by copyright. All rights reserved e.g. psoriasis and atopic dermatitis for which we get financial compensation paid to the department/hospital. The other authors declare that they have no competing interests.
Patient-Reported Outcome Measures in Dermatology: A Systematic Review
Acta Dermato Venereologica, 2021
This is the first study to systematically evaluate all published dermatology-specific (for use across skin conditions), patient-reported outcome measures against the goldstandard Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) criteria and make evidence-based recommendations for their use. The study found that no dermatology-specific patient-reported outcome measure can be unequivocally recommended for use. These results question the validity of the data collected using these patient-reported outcome measures, which has implications for clinical decision-making and research. By relying on data from existing patient-reported outcome measures of quality of life, the true impact of skin conditions on patients' lives may be underestimated. This study systematically reviewed all dermatologyspecific (used across skin conditions) patient-reported outcome measures and makes evidence-based recommendations for their use. The study protocol is registered on PROSPERO (CRD42018108829). PubMed, PsycInfo and CINAHL were searched from inception to 25 June 2018. The Consensus-based Standards for the Selection of Health Measurement Instruments (COS-MIN) criteria were used to assess the measurement properties and methodological quality of studies. A total of 12,925 abstracts were identified. Zero patientreported outcome measures were assigned to category A (ready for use without further validation), 31 to category B (recommended for use, but only with further validation) and 5 to category C (not recommended for use). There is no gold-standard dermatology-specific patient-reported outcome measure that can be recommended or used without caution. A new measure that can comprehensively capture the impact of dermatological conditions on the patient's life is needed.
Outcome Measures of Psoriasis in Clinical Trials: An Overview
Journal of Medical Science And clinical Research, 2016
Psoriasis is a common chronic inflammatory dermatological disorder resulting from interactions between genetic predisposition and triggering environmental factors. It affects approximately 1-3% of the population and poses a lifelong burden on those, affected. Psoriasis typically follows a relapsing and remitting course. It can occur at any age, although is uncommon in children (0.71%) but the majority of cases occur before 35 years. Psoriasis is associated with arthritis in a significant proportion of patients (reported in one study at 13.8%). Usually the psoriasis is not life threatening but it can be life ruining due to its visibility. In clinical trials, several outcome measures have been used to assess the severity of psoriasis. The common outcome measures include PASI (psoriasis area and severity index) score,
The Journal of investigative dermatology, 2015
Core outcome sets (COSs) are consensus-derived minimum sets of outcomes to be assessed in a specific situation. COSs are being increasingly developed to limit outcome-reporting bias, allow comparisons across trials, and strengthen clinical decision making. Despite the increasing interest in outcomes research, methods to develop COSs have not yet been standardized. The aim of this paper is to present the Harmonizing Outcomes Measures for Eczema (HOME) roadmap for the development and implementation of COSs, which was developed on the basis of our experience in the standardization of outcome measurements for atopic eczema. Following the establishment of a panel representing all relevant stakeholders and a research team experienced in outcomes research, the scope and setting of the core set should be defined. The next steps are the definition of a core set of outcome domains such as symptoms or quality of life, followed by the identification or development and validation of appropriate ...
Navigating the landscape of core outcome set development in dermatology
Journal of the American Academy of Dermatology
The development of core outcome sets (COS), i.e. a minimum set of 'core outcomes' that should be measured and reported in all trials or clinical practice of a specific condition, in dermatology is gathering pace. A total of 44 dermatology-related COS projects have been registered in the online Core Outcome Measures in Effectiveness Trials (COMET) database (http://www.comet-initiative.org/studies/search), and include studies on 26 different skin diseases. With the increasing number of COS in dermatology, care is needed to ensure the delivery of high quality COS that meet quality standards based on state of the art methodology. In 2015, the Cochrane Skin-Core Outcome Set Initiative (CS-COUSIN) was established. CS-COUSIN is an international, multidisciplinary working group, aiming to improve the development and implementation of COS in dermatology. CS-COUSIN has developed guidance on how to develop high quality COS for skin diseases, and supports dermatology-specific COS initiatives. Currently, 16 COS development groups are affiliated to CS-COUSIN following standardized COS development processes. To ensure successful uptake of COS in dermatology, researchers, clinicians, systematic reviewers, guideline developers and other stakeholders should use existing COS in their work.
The British journal of dermatology, 2014
This report provides a summary of the third meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in San Diego, CA, U.S.A., 6-7 April 2013 (HOME III). The meeting addressed the four domains that had previously been agreed should be measured in every eczema clinical trial: clinical signs, patient-reported symptoms, long-term control and quality of life. Formal presentations and nominal group techniques were used at this working meeting, attended by 56 voting participants (31 of whom were dermatologists). Significant progress was made on the domain of clinical signs. Without reference to any named scales, it was agreed that the intensity and extent of erythema, excoriation, oedema/papulation and lichenification should be included in the core outcome measure for the scale to have content validity. The group then discussed a systematic review of all scales measuring the clinical signs of eczema and their measurement properties, followed by a consensus vote on whi...
Clinical Outcome Measures of Psoriasis
2000
SUMMARY Several tools have been introduced in clinical trials to quantify the severity and the response to a given therapeutic regimen of both psoriasis and psoriatic arthritis. Each method present specific advantages and limitations. Here we will discuss some of the most popular clinical outcome measures of both psoriasis (Psoriasis Severity Index, Physi- cian Global Assessment, National Psoriasis Fundation-Psoriasis Score,